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The diagnosis depends on demonstrating maternal/neonatal or maternal/paternal platelet antigen 26 incompatibility with a maternal antibody to a paternal antigen. The most commonly detected 27 antibodies in Caucasians are those directed against human platelet antigen (HPA)-1a (80%) and HPA-28 5b (10-15%), which can allow prediction of at-risk fetuses. 6 Where results are not supportive but 29 clinical suspicion of FNAIT is high, further testing and management should be discussed with the 30 diagnostic laboratory. 31 32
The prenatal management of FNAIT has undergone a major shift over the past few years. There has 33
been an increase in the use of immunoglobulins following evidence of probable efficacy, 7 and as a 34 consequence, reduced use of invasive fetal testing and fetal blood sampling (FBS). 35 36
There is very little high quality evidence on which to base management of this condition, but advances 37 in treatment report very good outcomes. As FNAIT is very rare, the treatments are costly and adverse 38 consequences for the fetus potentially disastrous. This document considers the latest evidence in 39 relation to treatment options in the prenatal management of pregnancies at risk of FNAIT; specifically, 40 the role of screening, immunoglobulins, steroids, FBS and intrauterine platelet transfusion. Moreover, 41
whether scientific research has shown treatments to be of benefit to women and their babies, taking 42 into account how any benefit is balanced against possible risks. Severe FNAIT (with platelets less than 25  10 9 /l) occurs in 1 in 10 000 live births; 8 20% of these have 49 an ICH, up to 80% of which occur during pregnancy rather than in the neonate (14% before 20 weeks 50 of gestation and a further 30% before 30 weeks of gestation). 9 It is clear that the first pregnancy may 51 be affected by FNAIT and that the diagnosis is often only made after fetal or neonatal bleeding, or a 52 chance finding of thrombocytopenia. 53 54
The aim of screening pregnant women for FNAIT would be to detect the condition during the mother's 55 first affected pregnancy, and to reduce the risk of ICH or intrauterine death for that baby and 56 subsequent babies. The benefits of screening would need to outweigh the risks. Screening would be 57
for FNAIT due to anti-HPA-1a only, as it is the most common antibody and causes 95% of severe FNAIT 58
(with platelets less than 50  10 9 /l). Van den Akker et al. 37 reported good outcomes in ten neonates born with platelets less than 50  246 10 9 /l; four of whom had a sibling with an ICH. In a further 25 cases with platelets less than 50  10 9 /l 247 at birth, two had an ICH, but these occurred before IVIg was started at 28 weeks of gestation. 39 It will 248 be important to collect further data on the outcomes of babies with platelets less than 50  10 9 /l, who 249 have been managed with maternal IVIg 1 g/kg/week and no FBS, to ensure the safety of such an 250 approach universally. At present, centres vary in the use of FBS at all and also whether one or more 251 than one FBS procedure is undertaken. 252 253
Evidence for steroids or escalation of dose of IVIg 254 255
The role of steroids is controversial. As a first-line alternative to maternal IVIg, steroids do not reliably 256 raise fetal platelet counts. 40 Furthermore, one study 23 reported no benefit of adding dexamethasone 257 in cases in which no rise in platelet count had been obtained using IVIg 1 g/kg/week alone, but noted 258 significant adverse effects in mothers and in another study, 22 fetal oligohydramnios. Prednisolone has 259 been used without causing oligohydramnios and with fewer maternal adverse effects, although these 260 remain common. 8 Several series using steroids in addition to IVIg have been reported, 4,5 but numbers 261 in these are limited (Table 1) . In one randomised controlled study, 33 mothers with a previous baby 262 with an ICH were excluded, but other mothers had a baseline FBS and were separated into those with 263 fetal platelets less than 20  10 9 /l (high risk) and those with fetal platelets more than 20  10 9 /l 264 (standard risk). In the high risk pregnancies, giving prednisolone 1 mg/kg/day in addition to IVIg 1 265 g/kg/week showed some benefit; with a satisfactory increase in fetal platelet count in 82% of cases 266 compared with only 18% on IVIg alone. However, in standard risk pregnancies, there was no benefit 267 from the addition of steroids to IVIg. In mothers who had a previous baby with ICH due to FNAIT, a 268 trend towards higher platelet counts was found in those given double-dose IVIg 2 g/kg/week or IVIg 1 269 g/kg/week plus prednisolone. 8 Therefore, in the absence of sufficiently large randomised controlled 270 trials to achieve definitive evidence-based optimal treatment strategies, either treatment may be 271 considered as an option in high risk cases where escalation of treatment is desirable. Selection may 272 also depend on maternal adverse effects associated with steroids (e.g. psychosis, diabetes, 273 hypertension) and IVIg (e.g. severe allergy The prevalent approach for delivery is a precautionary one in that elective caesarean section at 37 322 weeks of gestation is the preferred mode of delivery with a course (two doses) of steroids prior to 323 caesarean section (indicated for lung maturity rather than to boost the fetal platelet count). Where a 324 woman is multiparous, induction of labour at 38 weeks of gestation with avoidance of rotational or 325 ventouse delivery, or fetal scalp blood sampling in labour is a reasonable alternative. The evidence to 326 help guide advice regarding mode of delivery is weak. 327 328
Elective caesarean section at 36-38 weeks of gestation for all women with anti-HPA-1a antibodies, 329 together with HPA-1a-negative platelet donors for the neonate if petechiae are present and/or the 330 platelet count is less than 35  10 9 /l has also been suggested, 3 in order to reduce trauma, reduce 331 © 2017 Royal College of Obstetricians and Gynaecologists exposure to HPA-1a antibodies at the end of pregnancy and procure HPA-1a-negative platelets at a 332 specified time. 
